Human Longevity announced a multi-year agreement with Genentech to conduct whole genome sequencing of tens of thousands of de-identified samples Read the full story

NewLink Genetics has inked a pharma deal potentially worth $1 billion with Genentech for the development of NLG919, NewLink's IDO pathway inhibitor. Read the full story

Genentech is the biotech subsidiary of Roche. Read the full story

Genentech has entered into biotech deals with Arrayit to purchase a drug discovery tool for $138,000. Read the full story

Biologics pharma deals Genentech to be part of a limited group of specialty pharmacies authorized to distribute Tarceva. Read the full story

Immunocore has entered into pharma deals involving a collaborative R&D and licensing agreement with Genentech for the discovery and development of multiple novel cancer targets using Immunocore’s ImmTAC technology. Read the full story

Genentech is a top biotech company, subsidiary of Swiss pharma giant Roche, and active in partnering, licensing in, biotech healthcare Read the full story

Roche is a top pharma company active in partnering, licensing and M&A in pharmaceuticals and biotechology Read the full story

Roche announced over 375 partnering / licensing deals since 2005, with over 24 deals in 2012 alone, whilst Genentech announced over 98 partnering / licensing deals since 2005 Read the full story

Roche, a top pharmaceutical/biotechnology company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story